George Vlachogiannis: Impact of BMI on Outcomes in Advanced Clear Cell Renal Carcinoma Treatment
George Vlachogiannis, Executive Editor of Cancer Control at Sage Publishing, shared a paper John Greene and colleagues authored on LinkedIn:
“Dr John Greene and colleagues from the University of Oxford investigated the impact of Body Mass Index (BMI) on survival outcomes in ~1,000 patients with advanced clear cell renal carcinoma (RCC) receiving systemic anti-cancer therapies within the National Health Service (NHS) in England.
– Patients with higher BMI (≥25 kg/m²) had significantly improved survival compared to those with lower BMI.
– Median survival: 17.9 months (BMI ≥25) vs. 12.6 months (BMI <25).
– The survival benefit was most pronounced in the first year of treatment.
– Findings support the “obesity paradox”, suggesting that excess weight may enhance response to certain targeted therapies.
Understanding how body composition influences cancer treatment could pave the way for personalized therapeutic approaches in RCC and beyond, advocating for further research on the underlying molecular mechanisms.”
Authors: John Greene et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023